COA on every batch · Same-day dispatch by 2PM EST · For in-vitro research use only
Menu
Studied For
Secretagogues and releasing analogs studied along the GH axis.
7 results
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid GHRH(1-44) sequence with a trans-3-hexenoic acid modification at the N-terminus. It has a molecular weight of 5136 g/mol and CAS number 218949-48-5. The modification enhances peptide stability and bioavailability while maintaining full GHRH receptor agonist activity. Research demonstrates tesamorelin binds to and activates the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells, stimulating synthesis and pulsatile release of endogenous growth hormone. Unlike exogenous GH administration, tesamorelin preserves the physiological feedback mechanisms of the GH-IGF-1 axis, maintaining pulsatile secretion patterns and hypothalamic-pituitary regulatory loops. Clinical research has documented tesamorelin’s effects on visceral adipose tissue, with studies demonstrating significant reductions in trunk fat measured by CT scan. Research also shows improvements in lipid profiles including triglycerides and cholesterol ratios, as well as reductions in markers of cardiovascular risk. Studies in lipodystrophy models demonstrate selective reduction of visceral fat without significant effects on subcutaneous adipose tissue. Emerging research explores tesamorelin’s cognitive effects, with studies showing improvements in executive function and verbal memory associated with increased IGF-1 levels, particularly in populations with reduced endogenous GH secretion. Each vial contains 10mg of lyophilized tesamorelin at greater than 99% purity, verified by independent HPLC and mass spectrometry analysis.
$94.99· ships same-day
Sermorelin is a synthetic 29-amino acid peptide corresponding to the first 29 amino acids of the 44-amino acid human growth hormone-releasing hormone (GHRH). It has a molecular weight of 3357.9 g/mol and CAS number 86168-78-7. Sermorelin retains full biological activity as the minimal fragment required for GHRH receptor binding and activation. Research shows sermorelin stimulates the anterior pituitary to synthesize and secrete growth hormone through binding to GHRH receptors on somatotroph cells. Studies demonstrate it preserves the natural pulsatile pattern of GH release and maintains negative feedback through somatostatin and IGF-1 pathways. This physiological regulation distinguishes its mechanism from direct GH administration. Preclinical and clinical studies document sermorelin’s effects on body composition, with research showing increases in lean body mass, reductions in adipose tissue, and improvements in sleep architecture, particularly deep wave sleep stages associated with peak GH secretion. Research in aging models demonstrates restoration of youthful GH secretion patterns. Additional research has explored sermorelin’s effects on bone mineral density, immune function markers, and cardiovascular parameters. Studies in growth hormone deficiency models show normalization of IGF-1 levels without supraphysiological GH exposure. Each vial contains 10mg of lyophilized sermorelin at greater than 99% purity, independently verified by HPLC and mass spectrometry.
$65.99· ships same-day
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, a molecular weight of 873.0 g/mol, and CAS number 87616-84-0. It was among the first synthetic growth hormone secretagogues discovered and acts as a potent agonist of the ghrelin/growth hormone secretagogue receptor (GHSR1a). Research demonstrates GHRP-6 stimulates growth hormone release from the anterior pituitary through direct activation of GHSR1a, a mechanism distinct from and synergistic with GHRH receptor activation. Studies show it suppresses somatostatin release while simultaneously stimulating GHRH release from the hypothalamus, producing robust GH pulses that exceed the response to GHRH alone. Preclinical research documents GHRP-6’s orexigenic (appetite-stimulating) effects through central ghrelin receptor activation in the arcuate nucleus, distinguishing it from more selective secretagogues like ipamorelin. Studies also show GHRP-6 influences cortisol and prolactin release, increases gastric motility, and enhances gastric acid secretion through vagal afferent pathways. Additional research has explored GHRP-6’s cytoprotective effects, with studies demonstrating cardioprotective activity in ischemia-reperfusion models, hepatoprotective effects in liver fibrosis models, and neuroprotective properties through modulation of inflammatory and apoptotic pathways. Each vial contains 5mg of lyophilized GHRP-6 at greater than 99% purity, verified by HPLC and mass spectrometry.
$23.99· ships same-day
